19-year-old Mohammad freed from transfusion dependence by CRISPR therapy

Mohammad, 19, born with beta-thalassemia, was treated at Berlin's Charité with the approved CRISPR medicine Casgevy — the first routine use of the gene-editing drug in Germany since its approval. He had needed a transfusion roughly every three weeks and is now transfusion-independent; his doctors are cautiously optimistic and will follow him for 15 years.